DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
APD421 is an investigational drug.
There have been 10 clinical trials for APD421. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2015.
The most common disease conditions in clinical trials are Postoperative Nausea and Vomiting, Vomiting, and Nausea. The leading clinical trial sponsors are Acacia Pharma Ltd and [disabled in preview].
There is one US patent protecting this investigational drug and nine international patents.
Recent Clinical Trials for APD421
|Study of APD421 With and Without Ondansetron||Acacia Pharma Ltd||Phase 1|
|Mass-balance Study of [14C]-APD421 in Healthy Volunteers||Acacia Pharma Ltd||Phase 1|
|Study of APD421 as PONV Treatment (Prior Prophylaxis)||Acacia Pharma Ltd||Phase 3|
Top disease conditions for APD421
Top clinical trial sponsors for APD421
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|APD421||Start Trial||METAP2 inhibitors and methods of treating obesity||SynDevRx, Inc. (Cambridge, MA)||Start Trial|
|APD421||Start Trial||Pyrimidinyl-diazospiro compounds||Convergence Pharmaceuticals Limited (Maidenhead, GB)||Start Trial|
|APD421||Start Trial||Organic compounds||INTRA-CELLULAR THERAPIES, INC. (New York, NY)||Start Trial|
|APD421||Start Trial||Drug device configured for wireless communication||Pop Test Abuse Deterrent Technology, LLC (Cliffside Park, NJ)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|